CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer
ACTIVE_NOT_RECRUITING
Status
Conditions
- Advanced Head and Neck Squamous Cell Carcinoma
- Lung Non-Small Cell Carcinoma
- Metastatic Lung Non-Small Cell Carcinoma
- PD-L1 Positive
- Recurrent Head and Neck Squamous Cell Carcinoma
- Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Stage III Lung Cancer AJCC v8
- Stage IIIA Lung Cancer AJCC v8
- Stage IIIB Lung Cancer AJCC v8
- Stage IIIC Lung Cancer AJCC v8
- Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Stage IV Lung Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8
- Unresectable Lung Non-Small Cell Carcinoma
- Advanced Squamous Non-Small Cell Lung Carcinoma
Interventions
- OTHER: Laboratory Biomarker Analysis
- BIOLOGICAL: Nivolumab
- BIOLOGICAL: Pembrolizumab
- BIOLOGICAL: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Sponsor
Roswell Park Cancer Institute